This clinical trial is focused on studying the effects of a medication called secukinumab on a skin condition known as hidradenitis suppurativa. Hidradenitis suppurativa is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where skin rubs together. The study aims to understand how effective and safe secukinumab is for people with moderate to severe forms of this condition. Secukinumab is given as a solution for injection under the skin.

The purpose of the study is to compare the long-term effects of continuous versus interrupted treatment with secukinumab. Participants who have already responded well to secukinumab in previous studies will continue to receive the medication, while others will receive a placebo. The study will monitor how long it takes for symptoms to return in those who stop the medication compared to those who continue it. The study will also keep track of any side effects, changes in laboratory test results, and vital signs to ensure the treatment is safe.

Participants in the study will receive injections of secukinumab or a placebo over a period of time, and their progress will be monitored regularly. The study is designed to last until 2026, allowing researchers to gather comprehensive data on the long-term effects of the treatment. This information will help determine the best way to manage hidradenitis suppurativa with secukinumab in the future.